The World Health Organization announced the resumption of clinical trials on hydroxychloroquine, nine days after having suspended them due to the publication of a study in the prestigious medical journal The Lancet. The suspension of the trials was to allow WHO to analyze the information available, and a decision was expected in mid-June.
But as The Lancet distanced itself from the study on Tuesday evening, admitting in a formal warning that "important questions" hovered over it, the WHO published its findings sooner than expected. "We are now fairly confident that we have not seen any differences in mortality," Soumya Swaminathan, WHO chief scientist, said on Wednesday during a virtual press conference from the headquarters of the organization in Geneva.
“No reason to change the protocol” of clinical trials
After analyzing "available data on mortality", the members of the Safety and Monitoring Committee considered "that there is no reason to modify the protocol" of clinical trials, insisted the Director General of WHO , Tedros Adhanom Ghebreyesus, during a virtual press conference. The Solidarity Trial Executive Group, which represents participating countries, "received this recommendation and approved the continuation of all dimensions of the trials, including on hydroxychloroquine," he said.
"The Lancet" has doubts about his study, but what does that change? https://t.co/ZXLHU74wSI
- 20 Minutes (@ 20Minutes) June 3, 2020Published on May 22 in The Lancet, the study is based on data from 96,000 patients hospitalized between December and April in 671 hospitals, and compares the condition of those who received treatment with that of patients who did not. had.
Health
Hydroxychloroquine: "The Lancet" has doubts about its study, but what changes?
World
Coronavirus: Hydroxychloroquine ineffective in preventing Covid-19, according to an American study
- Coronavirus
- Deconfinement
- Covid 19
- World
- Health
- Clinical test
- epidemic